Live signal feed

The chain others read separately, joined in time.

NIH grant → clinical trial → public-company event. We snapshot all three daily and surface the upstream move before the downstream one is news. Last snapshot 2026-11-03 · 41 signals · 80 grants, 154 trials, 10423 tickers indexed.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingINHD55% conf

INNO HOLDINGS INC. (INHD) — trial primary completion in ~28 days

Upstream (observed)
Clinical trial status (n/a) — Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients

↓ days–weeks to disclosure

Predicted downstream
SEC 8-K / press release (material trial update) (days–weeks)

trial ↗filings ↗

Trial → FilingAZN55% conf

ASTRAZENECA PLC (AZN) — PHASE2 primary completion in ~140 days

Upstream (observed)
Clinical trial status (PHASE2) — A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingBMY55% conf

BRISTOL MYERS SQUIBB CO (BMY) — PHASE2 primary completion in ~44 days

Upstream (observed)
Clinical trial status (PHASE2) — Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingVYGR55% conf

Voyager Therapeutics, Inc. (VYGR) — PHASE2 primary completion 21 days ago (readout window)

Upstream (observed)
Clinical trial status (PHASE2) — VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingVTVT55% conf

vTv Therapeutics Inc. (VTVT) — PHASE3 primary completion in ~149 days

Upstream (observed)
Clinical trial status (PHASE3) — Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingSNY55% conf

Sanofi (SNY) — PHASE2 primary completion in ~176 days

Upstream (observed)
Clinical trial status (PHASE2) — Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingTAK35% conf

TAKEDA PHARMACEUTICAL CO LTD (TAK) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingGMAB35% conf

GENMAB A/S (GMAB) — PHASE2 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingAKTS35% conf

Aktis Oncology, Inc. (AKTS) — PHASE1 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE1) — A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingBMY35% conf

BRISTOL MYERS SQUIBB CO (BMY) — PHASE2 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingGMAB35% conf

GENMAB A/S (GMAB) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingREGN35% conf

REGENERON PHARMACEUTICALS, INC. (REGN) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingAMGN35% conf

AMGEN INC (AMGN) — PHASE1 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE1) — Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingARWR35% conf

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) — PHASE2 protocol updated 4 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingAZN35% conf

ASTRAZENECA PLC (AZN) — PHASE3 protocol updated 4 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingAMGN35% conf

AMGEN INC (AMGN) — PHASE3 protocol updated 5 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingAMGN35% conf

AMGEN INC (AMGN) — PHASE3 protocol updated 5 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingAZN35% conf

ASTRAZENECA PLC (AZN) — PHASE3 protocol updated 6 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingABBV35% conf

AbbVie Inc. (ABBV) — PHASE2 protocol updated 7 days ago

Upstream (observed)
Clinical trial status (PHASE2) — Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingLLY35% conf

ELI LILLY & Co (LLY) — PHASE1 protocol updated 5 days ago

Upstream (observed)
Clinical trial status (PHASE1) — A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingVYGR35% conf

Voyager Therapeutics, Inc. (VYGR) — PHASE1 protocol updated 5 days ago

Upstream (observed)
Clinical trial status (PHASE1) — An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingLLY35% conf

ELI LILLY & Co (LLY) — PHASE3 protocol updated 6 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingBMY35% conf

BRISTOL MYERS SQUIBB CO (BMY) — PHASE3 protocol updated 7 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingSNY35% conf

Sanofi (SNY) — PHASE2 protocol updated 11 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingLNTH35% conf

Lantheus Holdings, Inc. (LNTH) — PHASE3 protocol updated 11 days ago

Upstream (observed)
Clinical trial status (PHASE3) — [18F]PI-2620 Phase 3 Histopathological Study

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingLLY35% conf

ELI LILLY & Co (LLY) — PHASE1 protocol updated 12 days ago

Upstream (observed)
Clinical trial status (PHASE1) — A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingNVS35% conf

NOVARTIS AG (NVS) — PHASE2 protocol updated 13 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingAZN35% conf

ASTRAZENECA PLC (AZN) — PHASE3 protocol updated 4 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Area heat50% conf

"obesity" heating up — 0 grants ($0), 33 active trials (14 started <12 mo)

Upstream (observed)
NIH grant velocity — 0 grants, $0 in window

↓ 12–24 mo to BD/commercial activity (directional)

Predicted downstream
Elevated M&A / licensing / IPO activity in this mechanism over 12–24 mo (12–24 mo)

Area heat50% conf

"Alzheimer" heating up — 11 grants ($323,634,614), 35 active trials (11 started <12 mo)

Upstream (observed)
NIH grant velocity — 11 grants, $323,634,614 in window

↓ 12–24 mo to BD/commercial activity (directional)

Predicted downstream
Elevated M&A / licensing / IPO activity in this mechanism over 12–24 mo (12–24 mo)

Grant → Trial42% conf

NIH-funded research entered the clinic: "Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin…"

Upstream (observed)
NIH RePORTER grant — NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES — NIAID CCMF allocation (FY2025, $118,430,841) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastati…"

Upstream (observed)
NIH RePORTER grant — FRED HUTCHINSON CANCER CENTER — SDMC: HIV Vaccine Trials Network (FY2025, $35,817,302) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Trea…"

Upstream (observed)
NIH RePORTER grant — FRED HUTCHINSON CANCER CENTER — SDMC: HIV Vaccine Trials Network (FY2025, $35,817,302) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refracto…"

Upstream (observed)
NIH RePORTER grant — FRED HUTCHINSON CANCER CENTER — SDMC: HIV Vaccine Trials Network (FY2025, $35,817,302) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder"

Upstream (observed)
NIH RePORTER grant — VANDERBILT UNIVERSITY MEDICAL CENTER — All of Us Research Program Data and Research Center (FY2025, $40,678,454) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "The Gut - PRO Study"

Upstream (observed)
NIH RePORTER grant — UNIVERSITY OF WISCONSIN-MADISON — ADRC Consortium for Clarity in ADRD Research Through Imaging (FY2026, $29,597,166) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Evaluation of a Decision-Support Tool for Blood Biomarker Testing for Alzheimer's Disease…"

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Pilot of Continuous Glucose Monitor-Augmented Food Is Medicine"

Upstream (observed)
NIH RePORTER grant — UNIV OF NORTH CAROLINA CHAPEL HILL — Leadership and Operations Center (LOC), AIDS Clinical Trials Group (FY2026, $34,692,031) · joined via same funded organization

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Grant → Trial42% conf

NIH-funded research entered the clinic: "Whole Food for Families: A Pilot RCT of a Dietary Guidelines-Based Intervention to Preven…"

↓ Grant→trial typically 1–3 yr (translational); now realized — next watch is phase readout.

Predicted downstream
phase advance / readout (12–24 mo)

trial ↗grant ↗

Area heat29% conf

"GLP-1" heating up — 0 grants ($0), 3 active trials (3 started <12 mo)

Upstream (observed)
NIH grant velocity — 0 grants, $0 in window

↓ 12–24 mo to BD/commercial activity (directional)

Predicted downstream
Elevated M&A / licensing / IPO activity in this mechanism over 12–24 mo (12–24 mo)

Area heat23% conf

"immunotherapy" heating up — 0 grants ($0), 2 active trials (1 started <12 mo)

Upstream (observed)
NIH grant velocity — 0 grants, $0 in window

↓ 12–24 mo to BD/commercial activity (directional)

Predicted downstream
Elevated M&A / licensing / IPO activity in this mechanism over 12–24 mo (12–24 mo)